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Abstract
Background: Pregnane X receptor (PXR) is a key transcription factor that regulates drug metabolizing enzymes
such as cytochrome P450 (CYP) 3A4, and plays important roles in intestinal first-pass metabolism. Although there is
a large inter-individual heterogeneity with intestinal CYP3A4 expression and activity, the mechanism driving these
differences is not sufficiently explained by genetic variability of PXR or CYP3A4. We examined whether epigenetic
mechanisms are involved in the regulation of PXR/CYP3A4 pathways in colon cancer cells.
Methods: mRNA levels of PXR, CYP3A4 and vitamin D receptor (VDR) were evaluated by quantitative real-time PCR
on 6 colon cancer cell lines (Caco-2, HT29, HCT116, SW48, LS180, and LoVo). DNA methylation status was also
examined by bisulfite sequencing of the 6 cell lines and 18 colorectal cancer tissue samples. DNA methylation was
reversed by the treatment of these cell lines with 5-aza-2’-deoxycytidine (5-aza-dC).
Results: The 6 colon cancer cell lines were classified into two groups (high or low expression cells) based on the
basal level of PXR/CYP3A4 mRNA. DNA methylation of the CpG-rich sequence of the PXR promoter was more
densely detected in the low expression cells (Caco-2, HT29, HCT116, and SW48) than in the high expression cells
(LS180 and LoVo). This methylation was reversed by treatment with 5-aza-dC, in association with re-expression of
PXR and CYP3A4 mRNA, but not VDR mRNA. Therefore, PXR transcription was silenced by promoter methylation in
the low expression cells, which most likely led to downregulation of CYP3A4 transactivation. Moreover, a lower
level of PXR promoter methylation was observed in colorectal cancer tissues compared with adjacent normal
mucosa, suggesting upregulation of the PXR/CYP3A4 mRNAs during carcinogenesis.
Conclusions: PXR promoter methylation is involved in the regulation of intestinal PXR and CYP3A4 mRNA
expression and might be associated with the inter-individual variability of the drug responses of colon cancer cells.
Background
Nuclear receptor families play a pivotal role in regulating
genes involved in drug metabolism and disposition. Preg-
n a n eXr e c e p t o r( P X R ,a l s ot e r m e dS X R ,P A R ,a n d
NR1I2 as its gene name) is a crucial regulator of various
phase I and phase II drug metabolizing enzymes and
drug transporters. PXR is expressed in liver, small intes-
tine and other organs. PXR, with a number of therapeutic
drugs and other xenobiotics as its ligands, dimerizes with
retinoid X receptor a (RXRa). The ligand-PXR-RXRa
complex binds to promoter and enhancer elements
located upstream of cytochrome P450s (CYPs) 3A
and 2C family members, UDP-glucuronosyltrans-
ferases (UGTs), sulfotransferases (SULTs), glutathione
S-transferases (GSTs), and ATP binding cassette (ABC)
drug transporters (reviewed in [1-3]).
Wide inter-individual variability has been documented
in the expression of hepatic CYP3A4 with respect to
basal and PXR-inducible activities. The genetic variability
of PXR and CYP3A4 is not sufficiently frequent to
explain the apparent inter-individual variability [4]. The
inter-individual variability in basal hepatic CYP3A4
expression may include variability in PXR expression,
as PXR is activated by endogenous steroid hormones
and bile acids. Inter-individual variability of CYP3A4
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any medium, provided the original work is properly cited.expression is also observed in human intestine. Interest-
ingly, a report using paired tissue samples of livers and
small intestines indicated no observed correlation
between the hepatic and small intestine CYP3A4 expres-
sion levels [5]. Another research group reported that a
majority of CYP3A4 resided in the proximal region of the
small intestine, and that the CYP3A4 protein levels
decreased dramatically in the distal small intestine [6].
These observations suggest the CYP3A4 is regulated
through tissue specific epigenetic regulation in normal
tissue. The aim of the present study is to find possible
and not yet fully elucidated mechanisms which regulate
heterogeneous basal PXR and CYP3A4 expression and
activity in cancerous tissues as well. Indeed, several stu-
dies previously found a fraction of genes that exhibited
inter-individual differences in transcript levels associated
with DNA methylation status [7,8].
DNA methylation of the CpG-rich sequence around
e x o n3o ft h ePXR gene is involved in the epigenetic
regulation of PXR in human neuroblastoma [9]. How-
ever, epigenetic regulation of PXR and CYP3A4 in
human gut is poorly understood. In order to determine
whether epigenetic mechanisms function in PXR and
CYP3A4 regulation and intestinal metabolism, we exam-
ined DNA methylation and mRNA expression of several
candidate genes on the PXR/CYP3A4 regulatory path-
way in human colon cancer cell lines and tissues.
Methods
Cell lines and tissue samples
Human colorectal cancer cell lines LS180, Caco-2,
HT29, HCT116, DLD-1, LoVo, SW48 and SW620 were
purchased from DS Pharma Biomedical Co., Ltd.
(Osaka, Japan). LS180 cells were cultured in E-MEM
medium (Invitrogen Corp., Carlsbad, CA) at 37°C under
an atmosphere of 5% CO2. The other cells were cultured
under conditions described elsewhere [10].
Eighteen pairs of cancerous and adjacent normal
mucosa were excised from surgical specimens of color-
ectal cancers. The cancerous and normal epithelia were
separated from stroma using crypt isolation [11]. All
samples were selected from the same series of cancers
as we used in a previous study [10]. All 18 patients with
colorectal cancers did not receive chemotherapy before
surgical resection. The study protocol was approved by
ethics committee of Iwate Medical University (molecular
analysis of gastrointestinal tumors and the surrounding
mucosa; reference number, H21-140).
Treatment with 5-aza-2’-deoxycytidine
LS180, LoVo, Caco-2, HCT116, HT29 and SW48 cells
were seeded at a concentration of 1 × 10
5 cells on a
100 mm dish. The next day, treatment of cells with 0, 0.5
or 5 μM5 - a z a - 2 ’-deoxycytidine (5-aza-dC) (Sigma
Chemical, St. Louis, MO) was started, and 5-aza-dC was
removed by changing the medium 24 h later. The cells
were harvested 4 days after removal of 5-aza-dC for
DNA and RNA extraction.
Quantitative real-time PCR analysis of basal CYP3A4, PXR
and VDR mRNA levels
Total RNA extraction, cDNA synthesis and real-time PCR
were carried out on the cells prepared above, by the same
methods as described previously [10]. mRNA levels of the
CYP3A4 (exon 3-4, Hs01546612_m1), PXR (exon 5-6,
Hs00243666_m1) and vitamin D receptor (VDR) (exon
10-11, Hs01045840_m1) were evaluated by TaqMan Gene
Expression Assays (Applied Biosystems, Foster City, CA).
In addition, the mRNA level of the PXR splicing variants
(exon 1a-2) was also examined by SYBR Green assays
using the following primers: 5’-GATTGTTCAAAGTG-
GACCCC-3’(forward) and 5’-TCCAGGAACAGACTC
TGTGT-3’. The mRNA level of the above target genes
was normalized to b-actin mRNA [10]. All samples were
analyzed in duplicate and average quantities of the gene
transcripts were used for calculation. Deviation of the
mRNA level of each sample was within 7% of the average.
DNA methylation analysis of the 6 colon cancer cell lines
and 18 colon cancer samples
We found CpG islands within the PXR (around exon 3
region), VDR (promoter region) and protein arginine
methyltrasferase 1(PRMT1) (promoter region) genes
using the CpG Island Searcher program [12,13]. A CpG
island was also detected in the 5’ untranslated region
(UTR) of the CYP3A4 gene (approximately 25 kb distal
to the transcription start site). We also found a CpG-
rich sequence in the promoter region of the PXR gene,
although this sequence did not strictly satisfy the criteria
for a CpG island [13,14]. The location of all CpG
sequences examined in this study are shown in Figure 1.
Genomic DNA extracted from the 6 cell lines and the
18 pairs of normal and colon cancer tissue samples was
modified by sodium bisulfite, and then each segment
including a CpG island or CpG-rich sequence was
amplified by PCR and subjected to direct sequencing.
The methylation status of the PXR promoter sequence
was also estimated by bisulfite sequencing on at least 7
individual DNA strands after subcloning of PCR pro-
ducts into the pCR4-TOPO vector using the TOPO TA
Cloning Kit for Sequencing (Invitrogen). A relative
methylation level of the PXR promoter was visually
determined by the density of each HpyCH4IV-digested
band using combined bisulfite restriction analysis
(COBRA) [15]. The methylation status of the PXR exon
3 region was also examined by the COBRA assay using
an HhaI digestion. All primer sequences are listed in
Table 1.
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Page 2 of 10Figure 1 Location of the CpG sequences examined. CpG sites (vertical bars), CpG islands identified by CpG island searcher (horizontal thick
lines) and transcription start sites within the 5’ prime region (curved arrows) are shown in the (a), PXR; (b), CYP3A4; (c), VDR; and (d), PRMT1
genes. The segments indicated by double-pointed arrows were examined for DNA methylation by bisulfite direct sequencing.
Table 1 Primers used for DNA methylation analysis
Gene Segment Primer sequence (5’-3’) Annealing Product
temp.(°C) size (bp)
1F GAAGATAATTGTGGTTATTTTTTGGTA 55 574
1R CCACCTCCCTAAATAATATTACT
2F GTTGTTTTTAGTGGTAAAGGATAGA 55* 602
2R CACACACATCTTTTAACTAAAACT
PXR 3F AGGATTTATTATTTTAAGGAGGGGTT 55 230
promoter 3R CCTTAAAACAATACCTCTAACCAT
4F GTAAGATTTGGAGATTTTTTATATTTG 55 318
4R CTATCCTTCTCTACTAATAAAAATAC
COBRA GTAGGGAGAATATAATGAGAATAA 55* 209
ACTAAAATAAAAACAATACTTCCTCTTCAC
PXR F ATTTTTTTATAGGAGGGTTATGAAA 55 292
exon 3 R TACACACRAACACCAACTCACATAT
CYP3A4 F GAGTTATGGTGGGTTTTATTTAG 55 438
5’UTR R TCTACATTTCCATCTAAAATACC
VDR 1F ATAATTTTAGGTTTTAGGAGGTAG 60 400
promoter 1R CCTAAACTAACCAAACCAAAACTT
2F GGGTTGTTTTTGTTTGTTAAAAGG 60 373
2R CTTATTACCCAAATACTAAACACT
PRMT1 F AGGAGAAAGGGGGGGTTTTGGT 55* 273
promoter R AACCCTTAAAAACTAAAAAACC
F, forward primer; R, reverse primer.
*Dimethyl sulfoxide (5%) was added to the PCR mixture.
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Basal mRNA levels of the CYP3A4, PXR and VDR genes in
the 6 colon cancer cell lines
Real-time PCR analyses revealed that the basal levels of
CYP3A4, PXR (exon 5-6), PXR (exon 1a-2) and VDR
mRNA were heterogeneous among the 6 cell lines
examined (Figure 2). The 6 cell lines were then classified
into two groups (high or low expression cells) based on
the basal level of PXR and CYP3A4 mRNA, because the
6 cell lines always showed either high PXR and CYP3A4
expression or low PXR and CYP3A4 expression. The
levels of CYP3A4 and PXR transcripts on high expres-
sion cells (LS180 and LoVo) were 7- to 35-fold and
40- to 5,000-fold higher than those on lower expression
cells (Caco-2, HT29, HCT116 and SW48), respectively.
These two groups also exhibited a difference in the
basal level of the VDR transcript, although this differ-
ence was not marked (3.5- to 6-fold). There was strong
Figure 2 Basal expression profile of colon cancer cell lines. Basal levels of (a), PXR exon 5-6; (b), PXR exon 1a-2; (c), CYP3A4; and (d), VDR
transcripts in LS180, LoVo, Caco-2, HT29, HCT116 and SW48 cells. The vertical axis indicates a relative transcript level (ratio to LS180 cells). The
transcripts indicated by * (PXR exon 5-6 transcript in SW48 cells and CYP3A4 transcript in HCT116 cells) were not detected and we estimated the
minimum detectable levels among gradually diluted calibration samples (0.00257 and 0.0399, respectively).
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(exon 5-6) and PXR (exon 1a-2) throughout all analyses.
Increased mRNA expression by 5-aza-dC treatment
In order to determine whether DNA methylation is
involved in the transcriptional regulation of these genes,
the 6 cell lines were treated with DNA demethylating
agent (5-aza-dC). The treatment with 5-aza-dC induced
a clear increase in CYP3A4 (28- to 116-fold) and PXR
(3- to 10-fold) transcripts in a dose-dependent manner
in the low expression cells, but not in the high expres-
sion cells (Figure 3). In particular, the CYP3A4 tran-
script of the low expression cells eventually reached the
levels seen in the high expression cells by 5-aza-dC
treatment. In contrast, 5-aza-dC had no marked effect
on VDR expression in any of the cell lines (0.5- to
1.2-fold increase). These results suggested that DNA
methylation is involved in the regulation of CYP3A4
and PXR, but not VDR, in the low expression cell lines.
DNA methylation status of the colon cancer cell lines
The bisulfite direct sequencing detected no DNA
m e t h y l a t i o ni nt h eVDR or PRMT1 promoter sequences
in the 6 cell lines. Partial methylation of the CYP3A4 5’-
distal region and full methylation of the PXR exon 3
region were equally observed among the 6 cell lines.
Therefore, the different expression profiles of the two
groups cannot be explained by methylation of these
sequences. On the other hand, the CpG-rich sequence
of the PXR promoter showed a different methylation
status among the 6 cell lines. Interestingly, the degree of
methylation of the PXR promoter (segments 1 and 2) in
Figure 3 Expression profile of colon cancer cell lines after 5-aza-dC treatment. Levels of PXR, VDR and CYP3A4 transcripts in (a), LS180; (b),
Caco-2; (c), HCT116; (d), LoVo; (e), HT29; and (f), SW48 cells. Cells were treated with 5-aza-2’-deoxycytidine (0, 0.5 or 5 μM). The vertical axis
indicates a relative transcript level (ratio to cells without 5-aza-dC treatment). Numbers in italics indicate relative transcript levels that were over
the maximum scale on the vertical axis. The transcripts indicated by * (PXR exon 5-6 transcript in SW48 cells and CYP3A4 transcript in HCT116
cells) were not detected and we estimated the minimum detectable levels among gradually diluted calibration samples.
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Page 5 of 10the high expression cells (LS180 and LoVo) was lower
than that in the low expression cells (Caco-2, HT29,
HCT116 and SW48) (Figure 4). Therefore, the details of
the methylation status of the PXR promoter were esti-
mated on individual DNA strands after subcloning
(Figure 5). We found that an HpyCH4IV site within seg-
m e n t2w a sas u i t a b l em a r k e rf o rt h eC O B R Aa s s a yt o
assess PXR promoter methylation, because the degree of
methylation of this site showed inverse correlation with
the levels of CYP3A4 and PXR expression.
The COBRA assay demonstrated that the treatment with
5-aza-dC resulted in decreased amounts of methylation of
the PXR promoter in a dose-dependent manner in the low
expression cells (Figure 6a). Therefore, the magnitude of
methylation was likely to be associated with the decreased
levels of CYP3A4 and PXR gene expression in all 6 cell
lines. These results suggest that the PXR gene was tran-
scriptionally silenced by methylation of the promoter CpG
sites and that the downregulation of the PXR protein
resulted in decreased expression of the CYP3A4 gene.
The PXR promoter methylation was not associated
with the profile of microsatellite instability (MSI) or
other methylated genes (Table 2). This suggested that
altered PXR methylation was accumulated during
Figure 4 DNA methylation profile of PXR as detected by direct sequencing. Methylation status of the PXR gene in the 6 colon cancer cell
lines and a cancerous tissue sample (255C) and its paired adjacent normal tissue sample (255N) detected by bisulfite direct sequencing. Open
and closed circles represent unmethylated and fully methylated CpG sites, respectively. Half-closed circles represent partially methylated CpG
sites. The methylation status of the CpG island (around exon 3) and CpG-rich promoter sequence (segments 1, 2, 3 and 4) are shown in the
upper and lower panels, respectively.
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and epigenetic events.
DNA methylation status of colon cancer tissue samples
No or slight methylation of the PXR exon 3 region was
detected in the normal colon tissue samples by direct
sequencing and the COBRA assay. The levels of methy-
lation in the cancer tissues were mostly higher than
those in the paired adjacent normal tissues (Figure 6b).
By contrast, the CpG-rich sequence of the PXR promo-
ter was partially methylated in normal tissues, and the
degree of methylation was decreased in the paired can-
cer tissues (Figure 6c). The decreased level of the PXR
promoter methylation suggested increased expression of
the PXR gene during colorectal carcinogenesis. There
were no differences in the clinicopathological findings
between the colorectal cancers with PXR methylation
and those without methylation.
Discussion
In the present study, 6 colon cancer cell lines showed
heterogeneous mRNA expression profiles and were able
to be classified into two groups with respect to their
basal levels of the PXR/CYP3A4 transcripts (high
expression cells, LS180 and LoVo; low expression cells
Caco-2, HT29, HCT116, and SW48). These results are
consistent with previous studies, in which LS180 and
Caco-2 cells were characterized as PXR-sufficient and
PXR-deficient cells, respectively [16,17].
Genetic polymorphisms in the regions that regulate
transcription are often a major cause of inter-individual
variability in the levels of transcripts. However, such
polymorphisms have not been frequently observed in
the human PXR or CYP3A4 genes, implying that certain
epigenetic mechanisms are involved in the regulation of
PXR and CYP3A4 expression. We found that the CpG-
rich sequence within the PXR promoter region is methy-
lated to different levels in high and low expression cells.
Importantly, the magnitude of this promoter methyla-
tion was inversely associated with the levels of PXR and
CYP3A4 expression. Furthermore, the levels of the PXR
and CYP3A4 transcripts in low expression cells were
mostly restored when DNA methylation was reversed
by treatment with 5-aza-dC. Although this CpG-rich
sequence did not strictly satisfy the criteria for a CpG
island, the most affected CpG sites were located in a
highly restricted region (segments 1 and 2) and these
CpG sites were proximal to several putative transcrip-
tion factor binding sites (such as Sp1 and hepatocyte
nuclear factor 4 alpha) [18-20]. Therefore, PXR gene
expression is most likely transcriptionally regulated by
methylation of these promoter CpG sites.
CYP3A4 is transactivated by functional interplays with
VDR-RXRa or PXR-PRMT1 [20-22]. CpG-island methy-
lation of the VDR or PRMT1 promoter was not detected
in these cell lines and the mRNA expression of VDR
was not affected by 5-aza-dC treatment. These observa-
tions imply that DNA methylation of PXR, but not VDR
or PRMT1, resulted in downregulation of the CYP3A4
mRNA in these colon cancer cells.
It is still uncertain whether re-expression of the
CYP3A4 by 5-aza-dC treatment was due to the re-
expression of some other genes than PXR. However,
PXR must be a candidate for methylation and reduced
expression of the PXR by promoter methylation, even if
partially, contributes to downregulation of the CYP3A4.
Indeed, several studies demonstrated that selective
downregulation of the PXR by siRNA reduces the basal
Figure 5 Detailed DNA methylation profile of PXR segment 2.
Detailed methylation profile of the PXR gene in the 6 colon cancer cell
lines and a cancerous tissue sample (255C) and its paired adjacent
normal tissue sample (255N). Methylation of each CpG site was
estimated by bisulfite sequencing on 7 or 8 individual DNA strands
after subcloning. Open and closed circles represent unmethylated and
methylated CpG sites, respectively. A ‘TATA’ indicates a putative TATA
box. A curved arrow indicates a transcription start site. ‘HpyCH4IV’
indicates restriction site using the COBRA assay.
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manner [23].
CpG islands in the exon 3 region were fully methylated
throughout the cancer cell lines and most cancer tissues.
Even after treatment of the cell lines with 5-aza-dC, no
increase in the PXR mRNA levels was observed in the
high-PXR expressing cell lines, LS180 and LoVo. This
strongly suggests that in human colon cancer cells, the
methylated CpG islands in the exon 3 play a much less
role in the epigenetic regulation of PXR, instead, promo-
ter methylation plays a pivotal role in its regulation.
In contrast, Misawa et al. previously demonstrated a dis-
tinct methylation profile of neuroblastoma cells, in which
mRNA expression of the PXR splicing variant (exon
1a-2) was specifically regulated by the methylation of the
exon 3 region rather than promoter methylation [9]. We
Figure 6 Methylation status of the PXR promoter and exon 3 regions, as detected by the COBRA assay. Unmethylated and methylated
DNAs are shown as U and M, respectively. PCR products that were not cut by the restriction enzymes are shown as UC. (a) PXR promoter
methylation was examined in the 6 cell lines after treatment with 5-aza-2’-deoxycytidine (0, 0.5 or 5 μM). (b) Methylation status of the CpG island
of the PXR exon 3 region in 6 of the 18 primary colorectal cancers (numbers are those for particular cases). DNA samples from normal and
cancerous tissue are shown as N and C, respectively. Note that a high degree of methylation was detected in cancerous, but not normal, tissue.
(c) Methylation status of the CpG-rich sequence of the PXR promoter region in 8 primary colorectal cancers. Note that a lower degree of
methylation was detected in cancerous tissue compared to normal tissue.
Table 2 Profile of Microsatellite instability (MSI),
mismatch repair (MMR) deficiency and promoter
methylation in 6 colon cancer cell lines
MMR
deficiency*
Methylation**
Cell lines MSI MLH1 MSH2 MLH1 p16 PXR
LS180 + + - M ? U
LoVo + - + U M U
Caco-2 - - - ? ? M
HT29 - - - U M M
HCT116 + + - U M M
SW48 + + - M M M
Summary of previous studies [27,28] and the present study (PXR methylation).
*Mismatch repair deficiency was associated with mutations or defects in
mRNA transcripts.
**Methylation status was defined as unmethylated (U) or methylated (M).
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(exon 5-6) and PXR (exon 1a-2) transcripts in the colon
cancer cells. Therefore, a tissue-specific DNA methyla-
tion profile is most likely involved in the transcriptional
regulation of the PXR gene.
DNA methylation of the PXR promoter was detected
in only 1 of the 18 colorectal cancer tissue samples. The
results reflect the genuine DNA methylation status,
because we examined pure cancerous and normal
epithelia using crypt isolation and directly compared the
DNA methylation status between paired epithelia.
Therefore, a low level of PXR promoter methylation,
which was observed in the high expression cells, appears
to be a common feature of colorectal cancers. We also
demonstrated that the level of PXR promoter methyla-
tion is decreased during carcinogenesis, since paired
adjacent normal tissues mostly showed higher levels of
PXR promoter methylation. We could not directly com-
pare DNA methylation status with the PXR mRNA
expression, because crypt isolation provided ethanol-
fixed epithelia and it was difficult to obtain fresh mRNA
samples. However, most cancer tissues exhibited a pat-
tern of promoter methylation quite similar to that
observed in cultured cells with high expression (LS180
and LoVo) (Figures 5 and 6c). Therefore, the association
between promoter methylation and transcriptional silen-
cing of the PXR gene is most likely applicable to pri-
mary colorectal cancers. As observed in the colon
cancer cell lines, the decreased level of PXR promoter
methylation most likely led to increased expression of
PXR mRNA in the colorectal cancer tissues. These
results are consistent with a recent study that showed
strong expression of PXR mRNA in colon cancers, with
great variability [24]. In contrast, Ouyang et al.f o u n d
that PXR expression was lost or greatly diminished in
many colon cancers using histochemical analysis [25].
Although the role of the altered PXR expression in col-
orectal carcinogenesis remains to be clarified, Zhou
et al. demonstrated that PXR plays an antiapoptotic role
in colon carcinogenesis by induction of multiple antia-
poptotic genes [26].
We cannot rule out the possibility that alterations of
the PXR methylation levels play direct roles in tumori-
genesis, because certain oncogenes or tumor suppressor
genes may be trascriptionally regulated by PXR. Partial
methylation of the PXR observed in adjacent normal
mucosa may be associated with “field defect” for carcino-
genesis. However, numerous studies have demonstrated
that ligand-binding activation or siRNA-mediated silen-
cing of the PXR can affect the activity of metabolic
enzymes including CYP3A4, without changes in the cell
proliferation capacity. Therefore, we think that altered
level of the PXR methylation does not provide a selective
growth advantage during colorectal cancer progression.
Interestingly, overexpression of PXR in the colorectal
cancer tissue samples was correlated with an increase in
UDP glucuronosyl transferases UGT1A1, UGT1A9 and
UGT1A10, and led to a marked chemoresistance to the
active metabolite of irinotecan (CPT-11) [24]. In addi-
tion, CYP3A4 and p-glycoprotein, which are transcrip-
tionally activated by PXR, play important roles in
intestinal first-pass metabolism and determine a drug’s
bioavailability. We hypothesized that PXR may play a
key role in the colon cancer cell response to anticancer
drugs by modulating expression of drug metabolizing
enzymes and transporters including UGT1A, CYP3A4
and p-glycoprotein. Therefore, DNA methylation of the
PXR promoter might be a good predictor of chemother-
apy outcome and toxicity in colorectal cancers.
Conclusions
PXR promoter methylation is involved in the regulation
of intestinal PXR and CYP3A4 expression. This methy-
lation might be associated with the inter-individual
variability of the drug response of colon cancer cells.
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